Every 10-Q that SELLAS Life Sciences Group, Inc. (SLS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLS filings page.
SELLAS Life Sciences Group, Inc. reported results for the quarter ended June 30, 2026, showing a continued development-stage profile with a stronger balance sheet. Cash and cash equivalents were $138.3 million, up from $71.8 million at December 31, 2025, largely driven by $82.9 million of warrant exercise proceeds. Total assets were $145.4 million against modest total liabilities of $7.7 million, resulting in stockholders’ equity of $137.7 million.
For the three months ended June 30, 2026, SELLAS incurred a net loss of $9.6 million (vs. $6.6 million a year earlier), and a six‑month net loss of $18.0 million (vs. $12.4 million). Research and development expenses rose to $6.3 million for the quarter and $11.4 million year‑to‑date, reflecting increased GPS manufacturing, clinical work on the REGAL AML study, and SLS009 trials. General and administrative expenses increased to $4.4 million for the quarter and $8.5 million for six months, including a $1.0 million arbitration-related charge.
The company states that, based on current plans, its cash is expected to fund operations for at least twelve months from issuance of the financial statements, while it continues late‑stage development of GPS and advances SLS009 into randomized Phase 2 studies in AML. Management also highlights substantial remaining potential milestones under its 3D Medicines and GenFleet licensing arrangements, although no new licensing revenue was recognized in the period.
SELLAS Life Sciences Group, Inc. reported a net loss of $8.4 million for the quarter ended March 31, 2026, as it continues late-stage oncology drug development. Operating expenses rose to $9.3 million, driven by higher GPS manufacturing and regulatory work and increased legal and public company costs.
Cash and cash equivalents increased to $107.1 million, boosted by $44.1 million from the exercise of 28.2 million warrants during the quarter, plus a further $7.5 million from warrant exercises after March 31. Management believes this liquidity will fund planned operations for at least twelve months and has also put a $150 million at-the-market equity program in place.
The company is advancing two key programs: the Phase 3 REGAL trial of GPS in acute myeloid leukemia, approaching its final overall-survival analysis, and a randomized Phase 2 trial of SLS009 in newly diagnosed AML following positive Phase 2a results in relapsed/refractory AML. SELLAS also highlights multiple FDA orphan and rare pediatric disease designations and an ongoing arbitration with 3D Medicines over GPS milestones.
SELLAS Life Sciences Group (SLS) reported Q3 2025 results. The company posted a net loss of $6.8 million (basic and diluted $0.06 per share) as operating expenses eased slightly to $7.1 million, with research and development at $4.2 million and general and administrative at $2.9 million. For the nine months, net loss was $19.2 million and operating cash use was $23.5 million.
Cash and cash equivalents were $44.3 million as of September 30, 2025. Subsequent financing included an October 2025 warrant inducement for net proceeds of about $29.1 million, which, together with quarter-end cash, is expected to fund current planned operations for at least the next twelve months. Earlier in 2025, the company raised $23.1 million net via a registered direct offering and $22.0 million net via a September warrant inducement, with additional warrant exercises contributing $8.7 million.
Pipeline updates highlight the Phase 3 REGAL study for GPS continuing per independent monitoring recommendations toward a final analysis at 80 events, and SLS009 Phase 2a data meeting primary endpoints with FDA guidance to initiate a randomized first-line AML study. As of November 11, 2025, shares outstanding were 142,442,239.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on immunotherapies for hematologic and solid tumors. For the six months ended June 30, 2025, the company reported a net loss of $12.4 million, used $16.4 million of cash in operations, and had $25.3 million of cash and cash equivalents with an accumulated deficit of $260.5 million. Management states these resources are not expected to be sufficient for at least the next 12 months, and substantial doubt about going concern exists.
Clinically, the company reported positive developments: the REGAL Phase 3 GPS study's independent data monitoring committee recommended continuation after its interim review and the final analysis will occur at 80 events. Separately, SLS009 met primary endpoints in a Phase 2 study with an overall response rate of 33% (40% at the 30 mg BIW dose) and particularly strong responses in patients with ASXL1 mutations (50% ORR); the FDA provided guidance to advance a randomized first-line trial. Recent financing included a January 2025 registered direct offering with net proceeds of approximately $23.1 million.